• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MediWound Ltd. (Amendment)

    1/8/24 7:05:37 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    SC 13G/A 1 zk2430753.htm SC 13G/A


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND
    AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    MEDIWOUND LTD.
    (Name of Issuer)

    Ordinary Shares, par value NIS 0.07 per share
    (Title of Class of Securities)

     
    M68830112
     
    (CUSIP Number)

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Deep Insight Limited Partnership
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     PN
     
     
     
     

    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.


    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Deep Insight Fund GP Limited Partnership
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     PN
     
     
     
     
     
    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.


    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Deep Insight GP Ltd.
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     CO
     
     
     
     
     
    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.


    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Deep Insight Management Ltd.
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     CO
     
     
     
     
     
    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.


    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Barak Ben-Eliezer
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     IN
     
     
     
     
     
    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.


    CUSIP NO. M68830112

    1
    Name of Reporting Persons/
    I.R.S. Identification Nos. of above persons (entities only).
     
     
     
    Dr. Eyal Kishon
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a)  ☒
       
    (b)  ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
     
    Israel
     
     
     
     
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person
    With:
    5
    Sole Voting Power
     
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
     
    959,652 Shares *
     
     
     
     
    7
    Sole Dispositive Power
     
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
     
    959,652 Shares *
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
     
    959,652 Shares *
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
     
    10.4%**
     
     
     
     
    12
    Type of Reporting Person :
     
     
     IN
     
     
     
     
     
    * See Item 4.
    ** Based on 9,219,261 Ordinary Shares issued and outstanding as of September 30, 2023 (as reported by the Issuer in Exhibit 99.1 to its Report on Form 6-K filed with the Securities and Exchange Commission on November 21, 2023). See Item 4.



    Item 1.

    (a)
    Name of Issuer:
    MEDIWOUND LTD. (the “Issuer”).

    (b)
    Address of Issuer’s Principal Executive Offices:
    42 Hayarkon Street, Yavne, Israel 8122745.

    Item 2.

    (a)-(c)
    Name of Person Filing, address and citizenship:

    The following entities are referred to as the “Reporting Persons” in this Statement:

    Deep Insight Limited Partnership (“Deep Insight”), an Israeli limited partnership, with a principal business address at 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Deep Insight Fund GP Limited Partnership (“Deep Insight GP LP”), an Israeli limited partnership, with a principal business address at 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Deep Insight GP Ltd. (“Deep Insight GP Company”), an Israeli private company, with a principal business address at 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Deep Insight Management Ltd. (“Deep Insight Management”), an Israeli private company, with a principal business address at 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Barak Ben-Eliezer, an Israeli citizen, with a principal business address at c/o Deep Insight Limited Partnership, 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Dr. Eyal Kishon, an Israeli citizen, with a principal business address at c/o Deep Insight Limited Partnership, 2 Rachel Imeinu St., Modiin, Israel  7177190.
     
    Each of the Reporting Persons are filing this Statement jointly with one another pursuant to an agreement annexed as Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on December 2, 2022.

    (d)
    Title of Class of Securities:

    Ordinary Shares, par value NIS 0.07 per share (the “Shares” or “Ordinary Shares”).
     
    (e)
    CUSIP Number:

    M68830112
     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4.
    Ownership

    The 959,652 Ordinary Shares reported herein include 408,397 Ordinary Shares that are issuable upon the exercise of warrants held directly by Deep Insight. Deep Insight GP LP is the sole general partner of Deep Insight, Deep Insight GP Company is the sole general partner of Deep Insight GP LP, Deep Insight Management is the management company of Deep Insight GP LP and each of Barak Ben-Eliezer and Dr. Eyal Kishon hold 50% of the outstanding shares of Deep Insight GP Company and Deep Insight Management. Deep Insight GP LP, Deep Insight GP Company, Deep Insight Management, Barak Ben-Eliezer and Dr. Eyal Kishon may be deemed to share voting and dispositive power with respect to the Ordinary Shares that are beneficially owned by Deep Insight. While they are included herein as Reporting Persons, Barak Ben-Eliezer and Dr. Eyal Kishon disclaim beneficial ownership of the Ordinary Shares reported by Deep Insight herein.

    Item 5.
    Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.



    Item 6.
    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary, Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.

    Item 9.
    Notice of Dissolution of Group

    Not applicable.

    Item 10.
    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    January 8, 2024

     
    Deep Insight Limited Partnership
       
     
    By: /s/ Barak Ben-Eliezer
     
    Name, Title: Barak Ben-Eliezer, Managing Partner
       
     
    Deep Insight Fund GP Limited Partnership
       
     
    By: /s/ Barak Ben-Eliezer
     
    Name, Title: Barak Ben-Eliezer, Managing Partner
       
     
    Deep Insight GP Ltd.
       
     
    By: /s/ Barak Ben-Eliezer
     
    Name, Title: Barak Ben-Eliezer, Director
       
     
    Deep Insight Management Ltd.
       
     
    By: /s/ Barak Ben-Eliezer
     
    Name, Title: Barak Ben-Eliezer, Director
       
     
    Barak Ben-Eliezer
       
     
    By: /s/ Barak Ben-Eliezer
       
     
    Dr. Eyal Kishon
       
     
    By: /s/ Dr. Eyal Kishon


    Get the next $MDWD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    6/2/2025$34.00Outperform
    Oppenheimer
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We continue to execute acr

    8/14/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers

    MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers Post hoc analysis published in Advances in Wound Care, provides clinical evidence supporting wound bed preparation as a critical step in the healing process YAVNE, Israel, August 13, 2025 (GLOBE NEWSWIRE) – MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of  "The Correlation Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers: A Post Hoc Analysis of the ChronEx Multicenter Randomized Controlled Trial", in Advances in Wound Care, a leading peer

    8/13/25 8:45:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Second Quarter 2025 Financial Results

    MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast Details Toll-Free:       

    8/4/25 7:30:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

    8/16/24 4:36:54 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/30/22 4:38:06 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

    Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

    12/29/22 1:11:07 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $MDWD
    SEC Filings

    View All

    Oppenheimer resumed coverage on MediWound with a new price target

    Oppenheimer resumed coverage of MediWound with a rating of Outperform and set a new price target of $34.00

    6/2/25 8:53:24 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Alliance Global Partners initiated coverage on MediWound with a new price target

    Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

    5/2/25 8:15:09 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Craig Hallum initiated coverage on MediWound with a new price target

    Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

    2/28/25 7:39:12 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    8/19/25 7:00:19 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    8/14/25 7:05:26 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by MediWound Ltd.

    6-K - MediWound Ltd. (0001593984) (Filer)

    5/21/25 7:07:42 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Leadership Updates

    Live Leadership Updates

    View All

    MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

    YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

    11/21/23 7:00:00 AM ET
    $ENLV
    $MDWD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

    YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

    11/8/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

    YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi

    3/16/23 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Financials

    Live finance-specific insights

    View All

    MediWound Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. "We continue to execute acr

    8/14/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound to Report Second Quarter 2025 Financial Results

    MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast Details Toll-Free:       

    8/4/25 7:30:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

    VALUE Phase III trial of EscharEx® in venous leg ulcers advancing as planned NexoBrid® manufacturing expansion on track; full operational capacity expected by year-end 2025 First quarter revenue of $4 million; full-year 2025 revenue guidance reaffirmed at $24 million Conference call today, May 21 at 8:30am Eastern Time YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We entered 2025 with strong execution across our clinical, commercial, and operational priorities, mainta

    5/21/25 7:00:00 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    11/14/24 7:55:11 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    SC 13G/A - MediWound Ltd. (0001593984) (Subject)

    10/23/24 2:57:43 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by MediWound Ltd.

    SC 13G - MediWound Ltd. (0001593984) (Subject)

    10/1/24 8:23:53 AM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care